Deprescribing antidepressants
Deprescribing is the planned stopping of a medicine, or a cut in its dose, when it may no longer be needed, its risks may outweigh its benefits, or you would like to try without it. It is done with a prescriber, as a process with a review before it and follow-up after it, and with antidepressants it usually means a slow taper rather than a sudden stop.
Also called: Deprescribing, Tapering off a medication, Medication review.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
This page describes the US system: FDA labels and US guidelines. Lists of risky medicines and approved products differ in other countries.
What is deprescribing?
What marks it off from going cold turkey is the shape of it. The decision is made with a prescriber, your whole medicine list is looked at before anything changes, one medicine is changed at a time, and someone follows what happens after each step. A 2015 systematic review in the British Journal of Clinical Pharmacology put it as the withdrawal of an inappropriate medication, supervised by a health care professional, with the goal of managing polypharmacy and improving outcomes.
Other words for the same thing are tapering off, discontinuation, stopping treatment, and in a clinic a medication review. Deprescribing is the word clinicians use. Patients more often say coming off. Most of the research behind the process was done on older adults taking several medicines at once, so the question on the rest of this page is what carries over to one antidepressant.
What are the benefits of deprescribing?
For antidepressants the trial that speaks to this is ANTLER, published in the New England Journal of Medicine in 2021. It followed 478 adults in UK primary care who felt well enough to consider stopping and who had either two or more past episodes of depression or two years or more on citalopram, fluoxetine, sertraline or mirtazapine. Over 52 weeks, 56% of those who came off became unwell again, against 39% of those who stayed on. That is a group at high risk of relapse to begin with, and close to half of the people who came off stayed well through the year, which is what makes the timing worth planning with your prescriber.
Across medicines in general, fewer of them means fewer chances of a side effect and fewer interactions. The research is more careful than that. A 2016 review in the British Journal of Clinical Pharmacology found that stopping unnecessary medicines did not change deaths overall in the randomized studies, and that deaths fell only where the plan was tailored to the individual patient. Those studies were in older adults on several medicines, and the authors read the whole picture as feasible and generally safe rather than as a treatment in itself.
What is the first step of the deprescribing process?
Listing everything you take and why. That is step one of the five-step protocol in the 2015 JAMA Internal Medicine paper: ascertain all drugs the patient is currently taking and the reasons for each one. The other four steps weigh your own risk of harm from medicines, compare the likely benefit of each medicine against its burden, pick for stopping first the ones with the worst balance and the lowest chance of withdrawal or rebound, then carry out the plan and watch closely for what follows.
Your pharmacist can do much of that review with you, and they see every prescription you fill, including ones from different prescribers. In the D-PRESCRIBE trial, pharmacists in 69 community pharmacies in Quebec went through the list with adults aged 65 and older and wrote to their doctors, and far more of the medicines came to an end than with usual care. The four medicines in that trial were sedative-hypnotics, first-generation antihistamines, glyburide and anti-inflammatories, so it says nothing about antidepressants directly. The change to a prescription still goes through the prescriber, and NIMH asks people not to stop a prescribed medication, even when they feel better, without the help of a health care provider.
What are the recommended deprescribing guidelines for elderly patients?
In the US the main list is the AGS Beers Criteria, updated in 2023 by an expert panel of the American Geriatrics Society in the Journal of the American Geriatrics Society. It names medications that are potentially inappropriate for adults 65 and older, across all ambulatory, acute and institutionalized settings of care apart from hospice and end-of-life care. It is written as a prompt for a conversation, not as a ban.
Antidepressants turn up in it in three places. Tricyclics and paroxetine sit among the strongly anticholinergic medicines the panel says to avoid. SSRIs, SNRIs and tricyclics are listed for people who have fallen or had a fracture, to avoid unless safer alternatives are not available. Mirtazapine, SSRIs, SNRIs and tricyclics are under use with caution because they can bring sodium down, with a request to watch sodium levels closely when a medicine is started or a dose changes.
The Lexapro label says the same about sodium in its own way: elderly patients may be at greater risk of clinically significant hyponatremia on SSRIs and SNRIs. For most elderly patients that label keeps the recommended dose at 10 mg once daily and does not provide for the rise to 20 mg that other adults can be given. Both are reasons to review the medicine with a prescriber, not reasons to stop it between appointments.
What medications should not be stopped abruptly?
Antidepressants are on that list, by their own US labels. The Zoloft label says to gradually reduce the dosage rather than stopping it abruptly whenever possible, and the Lexapro label says a gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. Both describe what can follow a stop, and particularly an abrupt one, the cluster known as antidepressant discontinuation syndrome: nausea, sweating, low or irritable mood, agitation, dizziness, sensory disturbances such as electric shock sensations, anxiety, confusion, headache, tiredness and trouble sleeping.
Withdrawal is built into the deprescribing protocol too. Its fourth step picks for stopping first the medicines with the lowest chance of adverse withdrawal reactions or disease rebound, which is another way of saying the rest need a slower plan. Lists of the five medicines never to stop suddenly differ from site to site, so the answer that matters is the list of what you actually take, gone through with your prescriber or pharmacist.
What to do
Bring one list to the appointment: every medicine and supplement you take, the dose, who prescribed it, and what you believe each one is for. Ask which of them still earns its place, which would be reviewed first, and how a reduction would be spread out and followed up. Write down the date of every change and how you felt in the days after it, because telling withdrawal from the illness coming back is hard even for a prescriber, and that record gives them something to go on. If your mood drops after a reduction, tell your prescriber without waiting for your next appointment. If you're having thoughts of harming yourself, contact emergency services or a crisis line straight away. In the US, call or text 988. In the UK, call Samaritans on 116 123. Elsewhere, call your local emergency number.
Read the guide to tapering off antidepressants safely
How withClaro helps
- Log how you feel each day, next to the dose you took
- Every dose change dated in one place
- Share a PDF report with your prescriber before your appointment
Get the withClaro app on the App Store
Related terms
Sources
- Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of deprescribing with network analysis: implications for future research and clinical practice. British Journal of Clinical Pharmacology, 2015.
- Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, Gnjidic D, Del Mar CB, Roughead EE, Page A, Jansen J, Martin JH. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine, 2015.
- Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. British Journal of Clinical Pharmacology, 2016.
- Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA, 2018.
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 2023.
- Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine, 2021.
- U.S. Food and Drug Administration. Lexapro (escitalopram) tablets and oral solution: prescribing information. FDA / DailyMed, 2026.
- U.S. Food and Drug Administration. Zoloft (sertraline) tablets and oral solution: prescribing information. FDA / DailyMed, 2025.
- National Institute of Mental Health (NIMH). Mental Health Medications. NIMH, 2024.
All glossary terms